Researchers at Scripps Florida identified a memory suppressor microRNA called miR-980, which regulates neuronal excitability and inhibiting it improves memory. The study found links between miR-980 and autism spectrum disorder, suggesting that the microRNA may contribute to the development of the condition.
Scientists at Scripps Research Institute have developed a device called LIGHTSABR that can screen millions of compounds in a week for about $500. The device overcomes technical challenges in miniaturized screening and allows users to adjust the dose of the compound being tested.
Researchers aim to optimize synthetic ERRγ activators for potency and selectivity to advance treatments for various diseases. Previous studies in animal models suggest increased expression of ERRγ improves exercise capacity and mitochondrial function.
The Iris and Junming Le Foundation has donated $500,000 to support the purchase of a powerful super-resolution microscope at Scripps Florida. This advanced technology will enable neuroscientists to see synapses between neurons with unprecedented detail, potentially leading to breakthroughs in Alzheimer's disease research.
Researchers at TSRI have solved a long-standing mystery about the 'relief-valve' that protects cells from swelling. The study reveals that VRAC is a complex structure with five protein subunits, which determines its relief-valve properties. Different cell types may need different forms of VRAC to cope with their environments.
Researchers at Scripps Research Institute and UC Berkeley have made a breakthrough in understanding the proteasome, a molecular machine responsible for breaking down toxic proteins. The new study reveals how a crucial enzyme, Rpn11, is activated to remove harmful proteins from cells, providing potential new therapies for diseases such ...
A new TSRI study defines an unexpected mechanism at work in an anti-autoimmune drug candidate, ozanimod. The researchers found that S1PR1 agonists directly target immune cells to slow the overproduction of proteins known to cause autoimmune disease.
Researchers at Scripps Research Institute reveal the three-dimensional structure of TRPV2 ion channel, shedding light on its role in detecting infection and inflammation. The study's findings pave the way for developing new therapies to treat autoimmune diseases.
Researchers at Scripps Research Institute have developed a new method for modifying complex drug molecules, known as strain-release amination. This technique has enabled the efficient synthesis of a promising cancer drug candidate, which was previously unsolvable due to its high difficulty and toxicity. The breakthrough also opens up n...
Researchers at TSRI have devised a new method for building potential drug molecules and organic compounds more efficiently and selectively. Amino acids can act as catalytic directing groups, streamlining the process and reducing reagent usage.
A TSRI study reveals that a specific endocannabinoid called 2-arachidonoylglycerol (2-AG) acts as a molecular switch to increase motivation to consume nicotine. By blocking its production, compounds like 1,2,3-triazole urea inhibitors may restore the brain's balance and reduce nicotine's effects.
The Scripps Research Institute scientists will use click chemistry to discover novel drug candidates, aiming for more selective and potent medicines. The research may lead to improved therapeutics and PET protocols for children with neurodevelopmental disorders.
Researchers discovered how nucleophosmin (NPM1) transforms between two forms: a disordered monomer and a folded pentamer, influenced by phosphorylation and partner binding
A new study by TSRI scientists suggests a potent new therapeutic approach for hard-to-treat breast cancers, targeting the enzyme casein kinase 1´ (CK1´), which is overexpressed in many breast cancer types. The study found that a highly selective and potent CK1´ inhibitor, SR-3029, triggers rapid tumor cell death.
A Scripps Research Institute scientist has been awarded $2 million to investigate the impact of aging on a unique type of nerve cell involved in memory. The study aims to understand how gene expression changes with age and may lead to the development of novel therapeutics for age-related diseases.
A team of researchers at TSRI tracked the development of a family of antibodies that bind and neutralize HIV. By understanding how these antibodies evolve over time, scientists may be able to design a vaccine that triggers a faster immune response.
Researchers at TSRI have discovered the dynamics of β2 adrenergic receptor (β2AR), a protein linked to asthma, obesity and type 2 diabetes. The study found that β2AR naturally fluctuates between its active and inactive states in the absence of any drug, and different drugs can either stimulate or inhibit signaling.
The Scripps Research Institute (TSRI) team has discovered a unique anti-diabetes compound that activates the GLP-1 receptor's G-protein pathway, potentially leading to a new type of diabetes treatment. The novel molecule P5 shows promise in boosting glucose tolerance with minimal insulin stimulation.
Researchers created detailed fingerprints of G protein-coupled receptors, revealing complex interactions with signaling mediators. This breakthrough could lead to precise control of therapeutic effects and minimize adverse side effects.
Mutations in the nuclear lamina have been linked to various diseases including muscular dystrophies, heart disorders, and premature aging. TSRI researchers aim to understand the nuclear lamina's composition and protein interaction network to develop therapies for these diseases.
Researchers at TSRI identified a mutant protein's incorrect interactions with other cellular neighbors, which disrupted its normal function. By removing these interactions, they partially restored the protein's normal function, suggesting new therapeutic targets to treat cystic fibrosis.
Scientists from TSRI have shown how a previously unknown process promotes infection in dangerous viruses, such as dengue, West Nile, and Ebola. They also point to an experimental antibiotic called duramycin that inhibits infection by these deadly viruses, all of which lack vaccines and treatments.
Scientists from Scripps Research Institute have found that the interaction between a pair of brain proteins has a substantial effect on memory formation. The study reveals that when these two receptors interact, the ghrelin receptor changes the structure of the dopamine receptor and alters its signaling pathway.
Researchers at TSRI are developing a potential heroin vaccine to block the drug's active products from reaching the brain. The vaccine trains immune system antibodies to recognize and bind to heroin molecules, reducing the risk of relapse in recovering addicts.
The study identified at least three different structural classes of compounds active against multidrug-resistant and extensively drug-resistant strains of tuberculosis. These new inhibitors target the reductive sulfur assimilation pathway, essential for the bacteria's survival in host defense systems.
Researchers at The Scripps Research Institute have identified four prototype antibodies targeting a weak spot on HIV, which could lead to an effective vaccine. Two of these antibodies use their basic germline structure to bind with the virus, potentially allowing patients with HIV to kick-start a useful immune response.
A team led by TSRI researchers identifies Piezo2 as the long-sought protein sensor for proprioception, allowing scientists to better understand this essential sense. The discovery may also lead to a deeper understanding of human diseases related to proprioception.
Researchers aim to advance understanding of intrinsically disordered proteins controlling cellular behavior and potential cures for devastating diseases such as Parkinson's and Alzheimer's. The initiative seeks to raise awareness about the societal impacts of these understudied proteins and develop new therapies.
Researchers discovered a mechanism where mesenchymal stem cells recruit and suppress macrophage activity to protect themselves from damage. This process allows macrophages to repurpose damaged mitochondria for their own survival, creating a mutually beneficial relationship between the two cell types.
A TSRI team has been awarded a $1.8 million grant to investigate the molecular mechanisms behind cancer metastasis. The research could lead to new approaches to help patients by targeting specific molecules involved in tumor cell survival and metastasis.
A new study from TSRI found that high levels of epidermal growth factor receptor (EGFR) encourage blood vessel growth in early tumor development, facilitating cancer cell dissemination and metastasis. The findings highlight the urgent need for new methods to diagnose cancers early and new treatments to fight growing metastases.
Researchers discovered how a mutant protein triggers nerve damage in CMT subtype CMT2D, a group of currently untreatable conditions. The study suggests future therapies may target this haywire protein to restore nerve function in patients with CMT.
A new study shows that increasing caveolin-1 levels in nerve cells improves learning and memory in aged mice. The researchers believe this could be a path toward treating age-related memory loss and other conditions such as Alzheimer's disease.
Researchers at The Scripps Research Institute have discovered a way to convert leukemia cells into cancer-killing immune cells using a rare human antibody. The induced NK cells can detect and eliminate cancer cells, offering a potential new therapy for leukemia and possibly other cancers.
Researchers at Scripps Research Institute in California and German institutes have partnered to develop rigorous genomics-based methods for analyzing human stem cells. The goal is to ensure high-quality induced pluripotent stem cells (iPSCs) are available for research and clinical use.
Matthew Disney, a professor at Scripps Research Institute, has won the Tetrahedron Young Investigator Award for his exceptional creativity and dedication to organic synthesis and bioorganic and medicinal chemistry. The award recognizes his lab's work on tackling difficult problems in biomedical science.
Matthew D. Disney's innovative approach uses cells as reaction vessels to synthesize treatments within disease-affected cells, offering highly specific and precise therapies. This technology has potential applications in treating over 30 incurable diseases, including ALS, fragile X syndrome, and Huntington's disease.
A new study reveals that gas chromatography mass spectrometry (GC-MS) fundamentally alters the samples it analyzes due to heat, affecting thousands of laboratories worldwide. The researchers used a data analysis platform to observe small molecules transforming and disappearing during an experiment meant to mimic the GC-MS process.
Researchers have uncovered a significant relationship between a chemical transmitting brain signals and genetic mutations in individuals with autism spectrum disorder. Targeting a specific serotonin receptor, 5-HT2cR, can reverse social deficits in mouse models of the autism risk gene Pten.
Researchers at Scripps Research Institute have discovered a class of compounds that can effectively treat chronic itch without inducing sedation. The new compounds target the kappa opioid receptor, which is associated with pain perception and stress responses.
Researchers at Scripps Florida Institute have been awarded $6 million to develop an innovative HIV/AIDS vaccine that has shown promise in animal models. The approach works by blocking key sites on the virus's surface, preventing it from attaching and invading human immune cells.
Researchers will explore how brain processes a wide range of odors to understand cognitive functions and behavior in humans. The study aims to shed light on the evolution of mammalian brains and their connection to human behavior.
A new study by the Scripps Research Institute has identified a specific molecule called RGS7 that controls morphine receptor signaling in brain cells. Without this protein, animals were more prone to morphine addiction. The findings suggest that RGS7 could be a potential drug target for developing less-addictive pain medications.
A recent study by TSRI researchers has uncovered a novel pathway between the cell's powerhouses (mitochondria) and the immune system. RIPK3, an enzyme involved in cell death, relays signals between mitochondria and NKT cells, regulating both cancer and inflammatory responses.
Researchers at Scripps Research Institute have received a nearly $4.5 million grant with the possibility of up to $10 million to complete preclinical studies on a new anti-migraine drug candidate. The compound has shown promising results in treating stress-induced migraine and may be developed into a once-a-day pill.
Researchers uncover structural details of how proteins interact to turn two signals into one, enabling fine-tuning of signal and drug action. The study provides crucial insights into nuclear receptor communication, paving the way for improved drug design.
Researchers have made a major advance toward creating an effective, long-lasting flu vaccine by inducing broadly neutralizing antibodies in animal models. The study's findings show that the vaccine candidate can produce powerful 'broadly neutralizing antibodies' against many influenza subtypes.
Researchers at TSRI found that Staphylococcus aureus develops resistance to arylomycin by switching on a previously uncharacterized set of genes, bypassing the essential protein Type I signal peptidase. This discovery highlights the built-in redundancies that help bacteria survive in many environments.
The discovery sheds light on how the virus evolved and spread across West Africa, revealing that most cases are caused by spillover infections from wild rodents to humans.
A team of scientists at Scripps Research Institute has devised an improved method to engineer therapeutic proteins into antibodies, which can persist long enough to be useful. The technique mimics evolution and harnesses the power of large numbers to select rare junction segments that allow inserted proteins to fold and function normally.